Pactimibe

Drug Profile

Pactimibe

Alternative Names: CS 505

Latest Information Update: 01 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Inc; Kyoto Pharmaceutical Industries
  • Developer Daiichi Sankyo Europe; Daiichi Sankyo Inc
  • Class Antihyperlipidaemics; Indoleacetic acids; Small molecules
  • Mechanism of Action Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Hyperlipidaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 26 Oct 2005 Discontinued - Phase-I for Atherosclerosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top